MRK

Merck & Co., Inc.

Pharmaceutical Preparations · SIC 2834CIK 310158Held by 22 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$65.01B

Net Income FY2025

$18.25B

EPS (Basic, as reported)

$7.30

Net Margin FY2025

28.1%

ROE FY2025

34.7%

Total Equity

$52.61B

Shares Out

2.47B

Business description

Merck & Co., Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 39,807 → 65,011 +5.6% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue39,80740,12242,29446,84047,99448,70459,28360,11564,16865,011

Cost of revenue(14,030)(12,912)(13,509)(14,112)(15,485)(13,626)(17,411)(16,126)(15,193)(16,382)

Research & development(10,124)(10,208)(9,752)(9,872)(13,558)(12,245)(13,548)(30,531)(17,938)(15,789)

Selling, general & administrative(9,762)(9,830)(10,102)(10,615)(10,468)(9,634)(10,042)(10,504)(10,816)(10,733)

Interest expense(693)(754)(772)(893)(831)(806)(962)(1,146)(1,271)(1,357)

Interest & investment income3283853432745936157365415343

Other income (expense), net(720)(12)402(139)8861,341(1,501)(466)24(151)

Pre-tax income4,6596,5218,70111,4648,79113,87916,4441,88919,93621,067

Income tax expense(718)(4,103)(2,508)(1,687)(1,709)(1,521)(1,918)(1,512)(2,803)(2,804)

Net income3,9202,3946,2209,8437,06713,04914,51936517,11718,254

EPS — basic$1.42$0.88$2.34$3.84$2.79$5.16$5.73$0.14$6.76$7.30

EPS — diluted$1.41$0.87$2.32$3.81$2.78$5.14$5.71$0.14$6.74$7.28

Shares outstanding — basic (M)2,7662,7302,6642,5652,5302,5302,5322,5372,5322,502

Shares outstanding — diluted (M)2,7872,7482,6792,5802,5412,5382,5422,5472,5412,507

Showing the latest 10 of 19 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.